Researchers have proposed a novel double-targeted HA-TPP/A nanocomplex that leads to the ubiquitin-dependent proteasomal degradation of Mut p53 by targeting mitochondrial damage, destroying its GOF activity, increasing the sensitivity of AMG510-induced tumor cell killing, and thus reducing the proliferation and migration of gastrointestinal cancer cells with KRAS-TP53 co-mutation [88]. The gene discussed is TP53; the disease is neoplasm.